ASCO Updates Mesothelioma Guidelines: Immunotherapy Doubles 5-Year Survival to 14% as Standard of Care

The American Society of Clinical Oncology published updated treatment guidelines for malignant pleural mesothelioma on January 8, 2025, formally establishing dual immune checkpoint inhibitor therapy as the standard first-line treatment for all histological subtypes.^[1] Five-year survival data now shows that immunotherapy doubles long-term survival rates from 6% with chemotherapy to 14% with nivolumab plus ipilimumab — a shift that changes the treatment landscape for the approximately 3,000 Americans diagnosed with mesothelioma each year.^[13]

What Are the Key Facts About the ASCO Mesothelioma Guideline Update?

• ASCO published the guideline update on January 8, 2025 in the Journal of Clinical Oncology, replacing prior recommendations that positioned chemotherapy as the default first-line treatment.^[1]
• Dual immunotherapy is now a strong recommendation: Nivolumab plus ipilimumab is recommended as first-line treatment for all histological subtypes of unresectable malignant pleural mesothelioma.^[1]
• Non-epithelioid patients should not receive chemotherapy unless immunotherapy is specifically contraindicated, based on dramatically superior outcomes with immunotherapy in this population.^[1]
• CheckMate 743 five-year data: 14% of immunotherapy patients alive at five years versus 6% of chemotherapy patients — more than doubling long-term survival.^[1]
• Durable responses: 17% of immunotherapy responders maintained their response at five years compared to 0% of chemotherapy responders.^[1]
• Pembrolizumab combination approved September 2024: Pembrolizumab plus pemetrexed and platinum chemotherapy became the second FDA-approved first-line immunotherapy regimen, with an objective response rate of 62% versus 38% for chemotherapy alone.^[1]
• Biomarkers should not guide treatment decisions: PD-L1 expression, tumor mutational burden (TMB), and microsatellite instability (MSI) should not determine whether a patient receives immunotherapy.^[1]
• FDA first approved nivolumab plus ipilimumab for unresectable malignant pleural mesothelioma on October 2, 2020, based on CheckMate 743 results.^[3]
• Non-epithelioid hazard ratio of 0.48: Immunotherapy reduced the risk of death by 52% for sarcomatoid and biphasic mesothelioma patients, the most aggressive subtypes.^[1]
• Median overall survival with the pembrolizumab combination was 17.3 months versus 16.1 months with chemotherapy alone, with a hazard ratio of 0.79.^[1]
• Approximately 3,000 Americans are diagnosed with mesothelioma annually, and these updated guidelines affect treatment decisions for virtually all newly diagnosed patients with unresectable disease.^[13]

What Does the ASCO Guideline Update Actually Recommend?

The ASCO guideline update, published in the Journal of Clinical Oncology, provides clear and specific recommendations that fundamentally change how oncologists should approach first-line treatment for unresectable malignant pleural mesothelioma.^[1] The update is based on a systematic review of evidence from multiple phase III clinical trials and represents a consensus among mesothelioma experts.

"This is the most meaningful shift in mesothelioma treatment I have witnessed in two decades. ASCO is not suggesting immunotherapy as an option — they are saying it should be the default. That distinction matters enormously for patients walking into their oncologist's office for the first time after diagnosis."

— David Foster, 18+ Years Mesothelioma Advocacy, Danziger & De Llano

The central recommendation is a strong recommendation for dual immune checkpoint inhibitor therapy — specifically nivolumab (an anti-PD-1 antibody) combined with ipilimumab (an anti-CTLA-4 antibody) — as first-line treatment. This applies across all histological subtypes: epithelioid, sarcomatoid, and biphasic.^[1]

For patients with non-epithelioid histology (sarcomatoid and biphasic subtypes), the guideline goes further: chemotherapy should not be offered as first-line treatment unless there is a specific medical contraindication to immunotherapy. This is a direct reversal from previous practice, where chemotherapy with pemetrexed and cisplatin was the default regardless of histology.^[1]

The guideline also addresses the pembrolizumab combination regimen — pembrolizumab plus pemetrexed and platinum-based chemotherapy — which the FDA approved in September 2024. This combination is now recognized as a second FDA-approved first-line option, giving oncologists and patients a choice between two immunotherapy-based approaches.^[1]

One of the most clinically significant clarifications is that biomarkers should not determine treatment selection. PD-L1 expression levels, tumor mutational burden, and microsatellite instability status should not be used to decide whether a patient receives immunotherapy. All eligible patients should be offered immunotherapy regardless of these markers.^[1]

What Does the CheckMate 743 Five-Year Data Show?

The CheckMate 743 trial is the landmark study that established the clinical evidence for nivolumab plus ipilimumab in mesothelioma. The five-year follow-up data, which informed the ASCO guideline update, provides the most comprehensive long-term survival evidence available for immunotherapy in this disease.^[1]

"When I see 14% of patients alive at five years with immunotherapy versus 6% with chemo, I think about what that means in real terms. For every 100 patients starting treatment today, immunotherapy means 8 additional people who will see their grandchildren grow up. That is not a marginal improvement — that is a transformation."

— David Foster, 18+ Years Mesothelioma Advocacy, Danziger & De Llano

Overall survival: Median overall survival was 18.1 months in the nivolumab plus ipilimumab arm compared to 14.1 months in the chemotherapy arm, yielding a hazard ratio of 0.74. This four-month improvement in median survival translates to a 26% reduction in the risk of death.^[1]

Five-year survival rates: At the five-year mark, 14% of patients treated with nivolumab plus ipilimumab remained alive compared to 6% in the chemotherapy group. This more-than-doubling of five-year survival represents one of the most significant improvements ever documented in mesothelioma clinical trials.^[1]

Non-epithelioid outcomes: The survival benefit was most dramatic for patients with sarcomatoid and biphasic histology. The hazard ratio for non-epithelioid patients was 0.48, indicating a 52% reduction in the risk of death. Five-year overall survival was 12% for the immunotherapy group versus just 1% for the chemotherapy group — a twelvefold improvement that underscores why the guidelines now recommend against chemotherapy for these patients.^[1]

Durability of response: Among patients who responded to treatment, 17% of immunotherapy responders maintained their response at the five-year mark. In contrast, 0% of chemotherapy responders maintained their response at five years. This durability demonstrates that immunotherapy can produce lasting disease control in a meaningful subset of patients, which chemotherapy alone cannot achieve.^[1]

How Does the Pembrolizumab Combination Compare?

The September 2024 FDA approval of pembrolizumab combined with pemetrexed and platinum-based chemotherapy added a second immunotherapy-based first-line regimen for mesothelioma. This combination takes a different approach — pairing a single checkpoint inhibitor with traditional chemotherapy rather than using dual checkpoint inhibition alone.^[1]

The pivotal trial data showed a median overall survival of 17.3 months for the pembrolizumab combination versus 16.1 months for chemotherapy alone, with a hazard ratio of 0.79. While the median survival improvement is more modest than that seen with nivolumab plus ipilimumab, the pembrolizumab combination demonstrated a notably higher objective response rate: 62% of patients responded compared to 38% with chemotherapy alone.^[1]

"Having two FDA-approved immunotherapy options is genuinely significant for patients. Some individuals may not tolerate dual checkpoint inhibitors, or their oncologist may prefer a regimen that combines immunotherapy with chemotherapy. The point is that chemotherapy alone should no longer be the starting point for any newly diagnosed mesothelioma patient."

— David Foster, 18+ Years Mesothelioma Advocacy, Danziger & De Llano

The choice between the two regimens depends on several factors including patient health status, histological subtype, and the treating oncologist's assessment. For non-epithelioid patients, the five-year data strongly favoring nivolumab plus ipilimumab makes that regimen the preferred choice. For epithelioid patients who are expected to respond well to chemotherapy, the pembrolizumab combination may offer the benefit of a higher initial response rate combined with immunotherapy's durability.^[1]

Earlier-phase studies, including KEYNOTE-028, had established the single-agent activity of pembrolizumab in mesothelioma, which laid the groundwork for testing the combination approach.^[4] The IND227 trial further explored pembrolizumab combinations in the mesothelioma setting, contributing to the body of evidence supporting immunotherapy in this disease.^[5]

Why Do the Guidelines Say Biomarkers Should Not Guide Treatment?

In many other cancer types, biomarkers like PD-L1 expression play a central role in determining which patients should receive immunotherapy. The ASCO mesothelioma guidelines take a different position: PD-L1, tumor mutational burden, and microsatellite instability should not be used to select or exclude patients from immunotherapy treatment.^[1]

This recommendation is based on the CheckMate 743 trial data, which showed that the survival benefit of nivolumab plus ipilimumab was observed across all PD-L1 expression levels. Patients with low or negative PD-L1 expression still benefited from dual immunotherapy. Using PD-L1 as a gatekeeper would inappropriately exclude patients who could benefit from treatment.^[1]

This is an important practical consideration. Some community oncologists who are less experienced with mesothelioma may default to ordering PD-L1 testing and withholding immunotherapy if the result is low — a practice that is appropriate for some other cancers but explicitly inappropriate for mesothelioma based on the current evidence. Patients and their families should be aware that a low PD-L1 result is not a reason to deny immunotherapy for mesothelioma.^[1]

What Does This Mean for Non-Epithelioid Mesothelioma Patients?

The guideline update is arguably most consequential for patients with sarcomatoid and biphasic mesothelioma — the non-epithelioid subtypes that have historically had the worst prognosis. For decades, these patients had extremely limited treatment options, as sarcomatoid mesothelioma responds poorly to chemotherapy and is generally not amenable to curative surgery.^[1]

The data now shows a complete reversal in the treatment hierarchy for these patients. The CheckMate 743 hazard ratio of 0.48 for non-epithelioid patients means that immunotherapy cut the risk of death in half compared to chemotherapy. The five-year survival rate of 12% with immunotherapy versus 1% with chemotherapy is among the most dramatic improvements documented for any mesothelioma treatment in any subgroup.^[1]

"For years, a non-epithelioid diagnosis felt like a dead end. Chemotherapy barely moved the needle for sarcomatoid patients. Now we have data showing that immunotherapy gives these patients a meaningful chance at long-term survival. One in eight non-epithelioid patients on immunotherapy was still alive at five years. With chemotherapy, it was one in a hundred."

— David Foster, 18+ Years Mesothelioma Advocacy, Danziger & De Llano

The guideline's explicit statement that chemotherapy should not be offered to non-epithelioid patients unless immunotherapy is contraindicated is a strong directive. It signals that offering chemotherapy alone to a sarcomatoid or biphasic mesothelioma patient is now below the standard of care when immunotherapy is available. Patients with these subtypes who are being offered only chemotherapy should seek a consultation at a mesothelioma treatment center with immunotherapy experience.^[10]

How Should Patients and Families Respond to These Guidelines?

For patients newly diagnosed with mesothelioma, these guidelines provide a clear framework for evaluating their treatment plan. The first step is confirming the histological subtype — understanding your diagnosis is essential for knowing which treatment recommendations apply to your specific case.^[11]

Ask your oncologist whether your treatment plan aligns with the current ASCO guidelines. If chemotherapy alone is being recommended as your first-line treatment, ask specifically why immunotherapy is not included. There may be a valid medical reason — but the guidelines say immunotherapy should be the starting point for all eligible patients.^[1]

Seek consultation at a specialized mesothelioma treatment center. Community oncologists treat mesothelioma rarely and may not be current on the latest guideline changes. NCI-designated cancer centers and high-volume mesothelioma programs are most likely to offer guideline-concordant treatment, including access to both approved immunotherapy regimens and ongoing clinical trials testing next-generation approaches.^[10]

Understand that treatment is only one part of the picture. A mesothelioma diagnosis triggered by asbestos exposure creates both medical needs and legal rights. Compensation through asbestos trust funds and legal claims can help cover the cost of immunotherapy treatment, travel to specialized centers, and ongoing care. With over $30 billion available in asbestos trust funds, pursuing compensation early gives families more resources when they need them most.

Timing matters for both treatment and legal action. Immunotherapy is most effective when started early in the disease course. Similarly, statutes of limitations restrict the time available to file legal claims. Starting both processes promptly provides the best chance for optimal medical outcomes and full financial recovery. Veterans with asbestos exposure may also qualify for VA benefits in addition to trust fund and legal compensation.

What Does the Future Hold for Mesothelioma Immunotherapy?

The ASCO guideline update codifies what has already changed in clinical practice, but research continues to push the boundaries further. Ongoing trials are investigating combinations of immunotherapy with surgery (neoadjuvant and adjuvant approaches), novel checkpoint targets beyond PD-1 and CTLA-4, and cellular therapies that may eventually complement or succeed current immunotherapy regimens.^[6]

The BEAT-meso trial is evaluating the addition of bevacizumab (an anti-angiogenesis agent) to immunotherapy combinations in mesothelioma, which could further improve outcomes if results are positive.^[6] Additional studies are investigating whether the sequence of immunotherapy followed by chemotherapy or chemotherapy followed by immunotherapy affects long-term outcomes, which could refine treatment planning further.

For patients today, the message is clear: immunotherapy is no longer experimental for mesothelioma. It is the guideline-recommended standard of care, supported by the strongest clinical evidence ever generated for this disease. Any patient diagnosed with unresectable malignant pleural mesothelioma should be evaluated for immunotherapy as a first-line treatment.^[1]

How Can You Take the Next Step?

If you or a loved one has been diagnosed with mesothelioma, understanding these guideline changes can help you ensure you are receiving the most current, evidence-based treatment available. Take our free case evaluation quiz to connect with experienced advocates who can help you navigate both treatment options and legal rights, or contact Danziger & De Llano at (888) 555-1234 for a confidential consultation.

The ASCO guideline update confirms that immunotherapy should be your starting point, not your last resort. Getting to the right treatment center, receiving the right regimen, and securing the financial resources to support your care are all decisions that benefit from expert guidance. Every consultation is free, and all legal representation is on a contingency basis — you pay nothing unless we recover compensation for you.

Frequently Asked Questions

References

1. ASCO Guideline Update: Treatment of Malignant Pleural Mesothelioma — pubmed.ncbi.nlm.nih.gov
2. ASCO Guideline DOI: Treatment of Malignant Pleural Mesothelioma — ascopubs.org
3. FDA Approves Nivolumab and Ipilimumab for Unresectable Malignant Pleural Mesothelioma — fda.gov
4. KEYNOTE-028: Pembrolizumab in Mesothelioma — pubmed.ncbi.nlm.nih.gov
5. IND227 Trial: Pembrolizumab Plus Chemotherapy in Mesothelioma — pubmed.ncbi.nlm.nih.gov
6. BEAT-meso Trial Results — pubmed.ncbi.nlm.nih.gov
7. National Cancer Institute - Mesothelioma Treatment — cancer.gov
8. National Cancer Institute - Malignant Mesothelioma — cancer.gov
9. American Cancer Society - Malignant Mesothelioma — cancer.org
10. Mesothelioma Treatment Centers - WikiMesothelioma — wikimesothelioma.com
11. Understanding Your Diagnosis - WikiMesothelioma — wikimesothelioma.com
12. Mesothelioma Quick Facts - WikiMesothelioma — wikimesothelioma.com
13. NCI SEER - Mesothelioma Cancer Statistics — seer.cancer.gov
14. NCCN - Malignant Pleural Mesothelioma Guidelines — nccn.org